Paul J. Diaz, a director at Centene Corporation, received an equity award of 2,771 restricted stock units on July 28, 2026, according to a regulatory filing. The award vests in full on the date of the company's 2027 annual meeting of stockholders. The transaction represents part of routine director compensation practices at the healthcare services provider.
Key Points
- NYSE: CNC
- Director Paul J. Diaz acquired 2,771 restricted stock units on July 28, 2026
- The award carries a $0 transaction price and vests at the 2027 annual stockholder meeting
- The restricted stock units represent direct beneficial ownership following the transaction
Director Equity Compensation at Centene
Paul J. Diaz, who serves as a director at Centene Corporation, disclosed the receipt of an equity award consisting of 2,771 restricted stock units on July 28, 2026. The award was granted at no purchase price to the director, indicating it was issued as part of the company's director compensation structure rather than a market transaction. This type of equity grant is standard practice at publicly traded healthcare companies to align director interests with shareholder outcomes and support board-level recruitment and retention.
The filing indicates that Diaz holds the restricted stock units in direct beneficial ownership form. Following the transaction reported in this disclosure, his total beneficial ownership position includes these 2,771 restricted stock units. The award represents a component of the compensation arrangements established by Centene's board of directors and compensation committee for its non-executive board members.
Vesting Schedule and Future Stockholder Meeting
The restricted stock units awarded to Director Diaz will vest in full on the date of Centene's 2027 annual meeting of stockholders, according to the filing disclosure. This vesting structure ties the director's equity compensation to the company's annual governance cycle, ensuring that the award becomes fully earned shares at a scheduled corporate event. The approach provides clarity regarding the timing of when the restricted stock units will convert into actual common shares held by the director.
Vesting at the annual meeting date is a common mechanism used by public companies to align director equity compensation with key governance milestones. This structure ensures that the equity grant remains subject to the director's continued service through the vesting date, reinforcing board continuity and commitment to shareholder value creation over the specified period.
Transaction Details and Beneficial Ownership
The filing documents that the transaction occurred on July 28, 2026, and involved the acquisition of 2,771 non-derivative securities in the form of restricted stock units. The transaction code recorded in the filing indicates an acquisition, consistent with the grant of equity compensation rather than a purchase or sale by the director. The $0 price notation reflects the fact that restricted stock units granted as compensation do not involve a cash purchase by the recipient.
Diaz's beneficial ownership position following the reported transaction consists entirely of these 2,771 restricted stock units held in direct form. The filing provides transparency regarding his equity stake in Centene and ensures compliance with Securities Exchange Act reporting requirements for company insiders and directors. Investors monitoring insider holdings can track these ownership changes through the company's regular Form 4 filings.
Centene Corporation Background
Centene Corporation operates as a healthcare services provider and trades on the New York Stock Exchange under the ticker CNC. The company is subject to Section 16 reporting obligations under the Securities Exchange Act of 1934, which require directors, officers, and beneficial owners of more than 10 percent of equity securities to disclose changes in their beneficial ownership positions. The filing of this Form 4 by Director Diaz fulfills these transparency and disclosure requirements.
As a publicly traded healthcare entity, Centene implements standard governance practices including director compensation through a combination of cash retainers, meeting fees, and equity awards. The equity component of director compensation aligns board member financial interests with long-term shareholder value and helps attract qualified directors to serve on the company's board of directors and its various committees.
Compliance and Insider Reporting Framework
The disclosure was executed by Christopher A. Koster acting as attorney-in-fact for Director Diaz, as indicated by the signature line on the Form 4 filing dated July 28, 2026. This filing method allows directors to authorize representatives to file required forms on their behalf while maintaining compliance with Securities and Exchange Commission regulations. The attorney-in-fact designation is a standard administrative practice for insider reporting at large public companies.
Form 4 filings represent formal statements of changes in beneficial ownership required under federal securities law. These disclosures are designed to provide investors with transparent information about trading activity and compensation arrangements involving company insiders, including directors. The requirement to file these statements creates a public record accessible through the SEC's Electronic Data Gathering, Analysis, and Retrieval system, allowing market participants to monitor insider equity positions and transactions.
Director Role and Board Participation
Paul J. Diaz's designation as a director at Centene indicates his participation in the company's governance structure and board oversight functions. Directors at public healthcare companies typically serve on the board of directors and may participate in committees focused on audit, compensation, risk management, and other strategic oversight areas. The equity compensation provided to directors reflects their responsibilities in overseeing company operations and representing shareholder interests.
Director compensation structures at healthcare companies often include base retainers, meeting attendance fees, and annual equity grants that vest over specified periods or at milestone dates. These arrangements are designed to support adequate compensation for the time commitment and fiduciary responsibilities associated with board service while encouraging directors to maintain meaningful equity stakes in the company. The vesting structure for Diaz's award ties his compensation to continued board participation through the 2027 annual meeting.
Restricted Stock Units as Equity Compensation
Restricted stock units represent a form of equity compensation that provides directors and executives with an interest in the company's common stock, subject to vesting conditions and restrictions. Unlike stock options, which require the holder to exercise the award and pay a strike price to acquire shares, restricted stock units represent actual equity ownership interests that vest according to specified schedules. Once vested, restricted stock units typically convert into common shares held by the recipient.
The use of restricted stock units in director compensation aligns the interests of board members with those of shareholders, as both groups benefit from appreciation in the company's stock price. The $0 transaction price for Diaz's award reflects the fact that it was granted as compensation rather than purchased through a market transaction. This equity award structure encourages directors to focus on long-term company performance and shareholder value creation rather than short-term stock price movements.
Securities and Exchange Act Reporting Obligations
Director Diaz is subject to Section 16 reporting obligations under the Securities Exchange Act of 1934, which requires certain company insiders to disclose their beneficial ownership of company securities. Directors, officers, and beneficial owners of more than 10 percent of any class of equity securities must file initial statements of beneficial ownership and subsequent Form 4 filings documenting changes in their holdings. These filing requirements exist to promote transparency and allow investors to monitor insider equity positions.
The Form 4 filing process is designed to be completed within two business days of the transaction date, though companies may establish earlier internal deadlines for compliance. The filing must disclose the transaction code, amount of securities involved, price paid or received, and the resulting beneficial ownership position. The SEC's EDGAR system makes these filings publicly available, allowing investors, analysts, and other market participants to access insider trading and compensation information for publicly traded companies.



Please wait processing your request...